BriaCell Therapeutics (BCTX) said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a "dramatic anti-tumor response."

The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with "eye-bulging" metastatic breast cancer.

The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.

The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.

BriaCell shares were up almost 17% in premarket activity on Tuesday.

Price: 1.4499, Change: +0.21, Percent Change: +16.93